Clinical Trial Update: Iressa Expanded Access Program (EAP) [Phase 3]

View source ↗

Summary

Update on AstraZeneca's Iressa (gefitinib) Expanded Access Program in Phase 3 for non-small-cell lung cancer, including metastatic disease, with the program sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-small-cell Lung | Phase 3 | Status: COMPLETED